Garnet Anderson

About

Dr. Garnet Anderson is Senior Vice President and Director of the Public Health Sciences Division at the Fred Hutchinson Cancer Research Center and holds the Fred Hutch 40th Anniversary Endowed Chair. She received her Ph.D. in biostatistics from the University of Washington in 1989 and has been a faculty member at Fred Hutchinson Cancer Research Center’s division of Public Health Sciences since that time. Her primary research interests include the design and analysis of randomized trials, women’s health, and chronic disease prevention. Dr. Anderson is best known for her leadership role in the Women’s Health Initiative, a national effort to test methods to reduce the risk of cancer, cardiovascular disease, and osteoporosis-related fractures in postmenopausal women. She contributed to pivotal findings in 2002 that menopausal estrogen-plus-progestin therapy increased the risk of breast cancer, coronary heart disease, stroke, and blood clots, which led to a significant reduction in hormone use. Her subsequent analyses estimated that these changes prevented 126,000 breast cancer diagnoses and saved approximately $35.2 billion in direct medical expenses in the U.S. over ten years. As principal investigator of the Fred Hutch-based WHI Clinical Coordinating Center, she oversees the integration of multiple studies within this large program, including the Life and Longevity After Cancer (LILAC) study examining long-term effects of cancer and its treatment among aging survivors. Dr.…

Research topics

• Internal medicine
• Medicine
• Oncology
• Immunology
• Cancer research
• Surgery
• Pharmacology
• Gastroenterology
• Urology
• Anesthesia

Selected publications

• Early Neurologic Recovery, Practice Pattern Variation, and the Risk of Endotracheal Intubation Following Established Status Epilepticus

  Neurology · 2021 · 13 citations

  OBJECTIVE: To quantify the association between early neurologic recovery, practice pattern variation, and endotracheal intubation during established status epilepticus, we performed a secondary analysis within the cohort of patients enrolled in the Established Status Epilepticus Treatment Trial (ESETT). METHODS: We evaluated factors associated with the endpoint of endotracheal intubation occurring within 120 minutes of ESETT study drug initiation. We defined a blocked, stepwise multivariate regr…

  PublisherOA PDFDOI

• Predicting Unbound Phenytoin Concentrations: Effects of Albumin Concentration and Kidney Dysfunction

  Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · 2019-05-08 · 12 citations

  articleSenior authorCorresponding

  Study Objective Several methods are available to predict unbound (free) phenytoin concentrations in patients with hypoalbuminemia; however, predictive methods have not been evaluated in patients with concurrent hypoalbuminemia and kidney dysfunction or in patients with mild to moderate (estimated glomerular filtration rate [ eGFR ] 30‐90 ml/min/1.73 m 2 ) kidney dysfunction alone. Thus the objective was to evaluate the accuracy and precision of predictive methods to estimate free phenytoin conce…

  PublisherDOI

• PB0674 The Impact of Suboptimal Adherence to Factor Replacement Therapy on Time Spent Below Target Factor Trough Levels: Simulations Using Population Pharmacokinetic Modeling

  Research and Practice in Thrombosis and Haemostasis · 2023-10-01

  articleOpen access
  PublisherDOI

• Supplemental Figure 2B from A Phase I Study of APX005M and Cabiralizumab with or without Nivolumab in Patients with Melanoma, Kidney Cancer, or Non–Small Cell Lung Cancer Resistant to Anti-PD-1/PD-L1

  2023-03-31

  preprintOpen access

  <p>Association between pre-treatment CD8+ T-cell density from available baseline tumor tissue (n=14) and the duration of time on treatment in days.</p>

  PublisherDOI

• Data from A Phase I Study of APX005M and Cabiralizumab with or without Nivolumab in Patients with Melanoma, Kidney Cancer, or Non–Small Cell Lung Cancer Resistant to Anti-PD-1/PD-L1

  2023-03-31

  preprintOpen access

  <div>AbstractPurpose:<p>PD-1/PD-L1 inhibitors are approved for multiple tumor types. However, resistance poses substantial clinical challenges.</p>Patients and Methods:<p>We conducted a phase I trial of CD40 agonist APX005M (sotigalimab) and CSF1R inhibitor cabiralizumab with or without nivolumab using a 3+3 dose-escalation design (NCT03502330). Patients were enrolled from June 2018 to April 2019. Eligibility included patients with biopsy-proven advanced melanoma, non–sma…

  PublisherDOI

Recent grants

• NIH Grant R01HD061944

  NIH · $3.1M · 2015

• NIH Grant M01RR000037

  NIH · $22.1M · 2009

• NIH Grant R21AT002077

  NIH · $499k · 2007

Frequent coauthors

• Alan J. Wilensky

  University of Washington

  37 shared

• René H. Levy

  Neurological Surgery

  36 shared

• Anne M Lynn

  33 shared

• Harriet M. Kluger

  30 shared

• Mario Sznol

  Yale University

  30 shared

• Sarah A. Weiss

  Helios Hospital Bad Saarow

  30 shared

• Andrew Acheampong

  Allergan (United States)

  28 shared

• Glyn D. Williams

  Stanford University

  27 shared

Awards & honors

• Fred Hutch 40th Anniversary Endowed Chair

Similar researchers at University of Washington

• William Barlowh-144
• Paula Diehrh-58
• Andrea Cookh-53